J Breast Cancer.  2022 Aug;25(4):318-326. 10.4048/jbc.2022.25.e31.

Characteristics and Prognosis of Estrogen Receptor Low-Positive Breast Cancer

• Kim MC
• Park MH
• Choi JE
• Kang SH
• Bae YK

• KMID: 2532788
• DOI: http://doi.org/10.4048/jbc.2022.25.e31

Abstract

Purpose
The updated American Society of Clinical Oncology/College of American Pathologists guideline for estrogen receptor (ER) testing recommends that breast cancer with ER expression in 1–10% of tumor cells should be reported as ER-low positive (ER^low), although limited data are available on the overall benefits of endocrine therapy. We investigated the clinicopathological characteristics and clinical outcomes of ER^low breast cancer and to compare them with those of ER-negative (ER^neg) and ER-high (> 10% of tumor cells, ER^high) breast cancers.
Methods
Consecutive patients with invasive breast cancer who underwent curative surgery between November 2007 and December 2014 were included. Clinicopathological characteristics and disease-free survival (DFS) of ER^low tumors were compared with those of ER^neg and ER^high tumors.
Results
Of the 2,309 cases included, 46 (2%), 643 (27.8%), and 1,620 (70.2%) were ER^low , ER^neg , and ER^high , respectively. ER^low tumors were associated with no special type of histology (p = 0.011), advanced pT (p = 0.017), pN (p = 0.009) and anatomic stages (p < 0.001), high grade (p < 0.001), negative/low progesterone receptor (PR) status (p < 0.001), human epidermal growth factor receptor 2 positivity (p < 0.001), high Ki-67 (p < 0.001), and recurrence (p = 0.006) compared to ER^high tumors. DFS was significantly dependent on ER status, and ER^low tumors showed poorer DFS than ER^high tumors (p = 0.001), however, there was no significant survival difference between ER^low and ER^neg tumors. Furthermore, DFS in ER^high patients was affected by hormone therapy (p < 0.001), while it was not affected in ER^low patients.
Conclusion
Patients with ER^low breast cancer have clinicopathological characteristics that differ from those with ER^high tumors. Although this study was limited by the small sample size of the ER^low group, no benefit from hormone therapy was observed in the ER^low group compared with the ER^high group.

Keyword

Breast Neoplasms; Estrogen Receptor; Immunohistochemistry; Prognosis